Jeuveau completed clinical trials before receiving FDA Approval. FDA Approval is considered the gold standard worldwide for efficacy and safety. Beyond these clinical studies, Jeuveau was first introduced to the Korean market in 2014 under the name Nabota, and so we have some good data as well about what happens when Jeuveau is used outside of closely controlled scientific studies. So far, there have been absolutely no adverse events (or complications) reported with Jeuveau – which most are attributing to the fact that this the same molecule as Botox, and with almost 20 years of use, we’ve gotten really good at using this product safely and effectively.